Juno Therapeutics shares soared more than 50 percent in premarket trading after The Wall Street Journal reported the biotech company is in talks to be acquired by Celgene.
Shares of Juno rose $26.71 to $72.31 in premarket trading on Wednesday morning. The Seattle-based company had a market share of about $5.2 billion as of Tuesday.
Celgene is seeking to broaden its portfolio of blood-cancer drugs before Revlimid, its top-selling drug, loses its patent protection, The Journal noted. Juno’s approach is focused on developing treatments that use the body’s immune system to fight cancer.
The acquisition discussions could result in a deal within weeks, although it’s unclear how much Celgene would pay for Juno, The Journal added.
Source: CBS News
Avivi joins Bayer fresh off a yearlong stint as chief marketing officer of Advance Auto Parts, which followed about three years spent as marketing chief of another auto parts company, Tenneco. Rounding out her nearly 30-year career in marketing are leadership roles at consumer goods giants Kimberly-Clark and Procter & Gamble.
Air Liquide S.A. (Paris) is continuing its development with the acquisition of Homecare activities in Belgium and the Netherlands. The two entities acquired in Belgium and the Netherlands support 10,000 patients living with respiratory insufficiency, sleep apnea syndrome or requiring infusion or nutrition treatments.
US-based Vertex Pharmaceuticals has agreed to pay approximately $4.9 billion in cash to acquire Alpine Immune Sciences, a compatriot biotechnology company focused on discovering and developing innovative, protein-based immunotherapies.
